BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)
Phase 1/2Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NSCLC
Conditions
NSCLC, Melanoma
Trial Timeline
Aug 3, 2022 → Jun 30, 2026
NCT ID
NCT05180799About BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta) is a phase 1/2 stage product being developed by BioAtla for NSCLC. The current trial status is active. This product is registered under clinical trial identifier NCT05180799. Target conditions include NSCLC, Melanoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05180799 | Phase 1/2 | Active |
Competing Products
20 competing products in NSCLC